Comment on “Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example With PCSK9 Inhibitors”

Drug Safety - United Kingdom
doi 10.1007/s40264-018-0702-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Reply to Ward and Colleagues’ Comment on “Using Human Experiments of Nature to Predict Drug Safety Issues: An Example With PCSK9 Inhibitors”

Drug Safety
ToxicologyPharmacology
2018English

Mice With Human Ectopic Artificial Livers (HEALs) to Predict Human Drug Metabolism and Drug-Drug Interactions

Science-Business eXchange
2011English

PCSK9 Peptide Inhibitors

Science-Business eXchange
2014English

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

Prm124 - Modelling Likely Cardiovascular Disease Mortality With Pcsk9 Inhibitors Using a Synthetic Population

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

Hurdles With Using in Vitro Models to Predict Human Blood-Brain Barrier Drug Permeability: A Special Focus on Transporters and Metabolizing Enzymes

Current Drug Metabolism
Clinical BiochemistryPharmacology
2012English

Correction To: Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents With ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug–Drug Interactions With Moderate CYP3A4 Inhibitors or Inducers

Paediatric Drugs
Child HealthPediatricsPerinatologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy